Transform Clinical Development with Remote Body Composition Data

Traditional trials rely on infrequent DEXA snapshots at baseline, midpoint, and endpoint. Prism enables continuous at-home monitoring with weekly or monthly measurements, providing richer data, better statistical power, and reduced participant burden without facility visits.

Track lean mass, fat mass, visceral fat, and skeletal muscle mass as primary or secondary endpoints with DEXA-equivalent precision

Enable at-home monitoring to reduce participant burden and improve retention throughout long-duration trials

Capture weekly or monthly measurements instead of infrequent DEXA snapshots for better temporal resolution

Generate DEXA-equivalent data at a fraction of the cost and operational complexity of facility-based assessments

Regulatory agencies and payers increasingly demand real-world evidence beyond controlled trials. Prism enables pharmaceutical companies to collect body composition data from thousands of patients in real-world settings, demonstrating drug effectiveness and supporting formulary access.

Deploy body scanning at scale across diverse patient populations in real-world treatment settings

Demonstrate real-world drug effectiveness beyond controlled trial settings with longitudinal outcomes data

Track long-term outcomes (12+ months) with continuous at-home monitoring without facility requirements

Generate compelling data for payer negotiations and guideline committees that supports market access

Digital health partnerships create competitive advantage. Prism enables pharmaceutical companies to provide body composition monitoring as a value-added service to demonstrate superior outcomes (e.g., muscle preservation on GLP-1s) that differentiate from competitors and support patient adherence.

Provide body composition monitoring as a value-added service to prescribers and patients using your medications

Demonstrate superior outcomes (e.g., muscle preservation on GLP-1s) compared to competitor drugs with objective data

Build co-marketing programs with digital health partners using objective outcome data that drives prescriptions

Support patient adherence by providing engaging progress tracking that keeps patients on therapy longer

Post-market surveillance identifies safety signals and opportunities for label expansions. Prism enables monitoring of body composition changes across thousands of patients in real-world use, detecting adverse events, identifying responder populations, and generating data for expanded indications.

Track long-term body composition effects across thousands of patients in real-world post-market settings

Identify subpopulations with differential response patterns that may warrant label expansions or dosing adjustments

Detect safety signals (e.g., excessive muscle loss) in real-world use before they become widespread problems

Generate data to support label expansions or dosing optimizations based on real-world body composition outcomes